In this webinar, members of the Pure MHC research team will present and discuss data and learnings drawn from decades of experience identifying and validating HLA peptide targets for therapeutic development. Special emphasis will be given to mitigating risk in preclinical target selection for oncology and infectious disease indications.
Participation is free, however registration is required before May 18, 2021
10:50 Q & A
Complete the form below and click “Register Now” to save your seat: